Jason O'Byrne

Chief Financial Officer

Caribou Biosciences, Inc.Vir Biotechnology, Inc.

Insider activity · 24 months0 buys2 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 1 saleDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 1 saleMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (2 ops.)

€46k

Latest filing published 23 Mar 2026 for Vir Biotechnology, Inc.. Read the official filing

Filing timeline

BuySale

Jason O'Byrne

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Jason O'Byrne: trading record in brief

Filings by Jason O'Byrne span 2 companies, the busiest being Vir Biotechnology, Inc. and Caribou Biosciences, Inc. We count 8 filings; the first trade dates from 8 February 2022 and the latest from 20 March 2026.

The open-market record consists of 2 sales worth €46k, with no purchase. Besides market trades, the filings include 4 share grants and 1 option exercise. So far in 2026, the count stands at no purchases and 1 sale.

Most recently, on 23 March 2026, the filings show a transaction in Vir Biotechnology, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.